Nanopath has raised $10.0M in total across 1 funding round.
Nanopath's investors include Aleph VC, Alumni Ventures, AME Cloud Ventures, Battery Ventures, Catapult Capital, Citi Ventures, Flybridge Capital Partners, Foundry Group, Hardware Club, Hillsven, Norwest Venture Partners, OurCrowd.
Nanopath is an early-stage molecular diagnostics company developing a first-in-class platform for scalable, point-of-care disease diagnosis, focused on women's health issues like urinary tract infections (UTIs), pelvic, and gynecologic infections.[1][2][4] The platform uses an ultrasensitive optical nanobiosensing technology that detects pathogens and antibiotic resistance markers directly from samples like urine in 15 minutes, without needing bacterial culture or nucleic acid amplification, serving clinicians and patients to enable rapid, affordable testing in a single office visit.[2][3][4] With over $21M raised in venture capital and federal funding (including a $10M Series A), 17 employees, and FDA Breakthrough Device Designation, Nanopath shows strong growth momentum from Dartmouth spinout to commercialization stage, headquartered at MIT's The Engine.[4][5][6]
Nanopath was co-founded by women scientists Dr. Alison Burklund and Dr. Amogha Tadimety, who developed the core nanobiosensing platform during their Ph.D. research at Dartmouth College as fellows in the Ph.D. Innovation Program.[4][5] Driven by a vision to translate bench research into market impact for equitable health improvement—starting with women's health gaps like slow UTI diagnostics—the duo spun out the company, addressing gender equality and the need for point-of-care molecular tools.[2][4][5] Early traction came via NSF SBIR Phase I/II awards in 2022 for UTI diagnostics, NSF I-Corps validation, and residency at MIT's The Engine, a selective launchpad for tough tech startups, building to a $10M Series A in 2023 co-led by Norwest Venture Partners and Medtech Convergence Fund.[3][4][5]
Nanopath rides the point-of-care diagnostics trend, fueled by demands for rapid, decentralized testing post-COVID, health equity pushes, and antimicrobial resistance crises, where traditional culture-based methods delay UTI treatment by days—affecting millions, especially women.[2][3] Timing aligns with advanced manufacturing adoption in medtech (via MDIC collaboration) and tough tech funding surges at hubs like MIT's Engine, positioning it to disrupt $10B+ molecular diagnostics market by making amplification-free, affordable tools standard for women's health and beyond.[4] It influences the ecosystem by pioneering nanobiosensors for infections, inspiring gender-focused biotech spinouts, and bridging academia-to-market via federal programs like SBIR/I-Corps.[3][5]
Nanopath is primed to launch its UTI platform commercially, leveraging FDA designation, Series A funds for team/clinical partnerships, and manufacturing scale-up to capture women's health screening.[5][6] Trends like AI-enhanced biosensors, global AMR fights, and POC expansion will propel it, potentially evolving into a multi-infection platform influencing routine OB/GYN care. As a women-led tough tech leader, its trajectory could redefine equitable diagnostics, delivering on the promise of single-visit, actionable insights that sparked its Dartmouth origins.
Nanopath has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in August 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2022 | $10.0M Series A | Aleph VC, Alumni Ventures, AME Cloud Ventures, Battery Ventures, Catapult Capital, Citi Ventures, Flybridge Capital Partners, Foundry Group, Hardware Club, Hillsven, Norwest Venture Partners, OurCrowd, Recursive Ventures, SignalFire, SNR, The Hit Forge, Tribeca Venture Partners, UpWest, Clark Landry, Curtis Lee, Evan Williams, Michael Birch, Oliver Thylmann |
